or Try an Advanced Search...

    Hematologic Malignancies Stocks List

    Symbol Grade Name % Change
    SLS B SELLAS Life Sciences Group, Inc. -1.48
    TCRX B TScan Therapeutics, Inc. -1.04
    FATE D Fate Therapeutics, Inc. -0.98
    HOWL C Werewolf Therapeutics, Inc. -0.16
    CLLS B Cellectis S.A. 0.00
    APTO F Aptose Biosciences, Inc. 0.84
    INCY D Incyte Corporation 1.26
    PRTC B PureTech Health plc 1.79
    AFMD D Affimed Therapeutics B.V. 2.26
    KYMR D Kymera Therapeutics, Inc. 3.03
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Solid Tumors Cancer Life Sciences Medicine Acute Myeloid Leukemia Biotechnology Clinical Medicine Immunology Tumors Of The Hematopoietic And Lymphoid Tissues Biology Blastoma CD19 Chronic Lymphocytic Leukemia Glioblastoma Health Sciences Hematopoietic Stem Cell Immune System Immunotherapies Lymphocytic Leukemia

    Related ETFs - A few ETFs which own one or more of the above listed Hematologic Malignancies stocks.

    Symbol Grade Name Weight
    SURI D Simplify Exchange Traded Funds Simplify Propel Opportunities ETF 7.52
    IDNA C iShares Genomics Immunology and Healthcare ETF 3.66
    FBT D First Trust Amex Biotech Index Fund 3.29
    BIS D ProShares UltraShort Nasdaq Biotechnology 2.32
    XBI D SPDR S&P Biotech ETF 2.31
    View all Hematologic Malignancies ETFs...
    Compare ETFs
    Compare FBT to XBI Compare IDNA to BIS Compare SURI to FBT

        Hematologic Malignancies Stocks Recent News

        Date Stock Title
        May 3 FATE Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
        May 3 KYMR Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript
        May 3 KYMR Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
        May 3 KYMR Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should Know
        May 3 HOWL Werewolf Therapeutics GAAP EPS of -$0.39, revenue of $0.74M
        May 3 HOWL Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
        May 3 KYMR Kymera Therapeutics, Inc. (KYMR) Q1 2024 Earnings Call Transcript
        May 3 KYMR Kymera Therapeutics Inc (KYMR) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
        May 3 INCY Q1 2024 Insight Enterprises Inc Earnings Call
        May 2 CLLS Cellectis announces CFO departure
        May 2 CLLS Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
        May 2 TCRX AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
        May 2 KYMR Kymera Therapeutics GAAP EPS of -$0.69 beats by $0.04, revenue of $10.3M misses by $2.75M
        May 2 KYMR Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
        May 1 KYMR Kymera Therapeutics Q1 2024 Earnings Preview
        May 1 INCY Incyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript
        May 1 SLS Sellas reports positive Phase 2 data from AML study, files for patent
        May 1 TCRX TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
        May 1 SLS SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
        Apr 30 INCY Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Solid Tumors Cancer Life Sciences Medicine Acute Myeloid Leukemia Biotechnology Clinical Medicine Immunology Tumors Of The Hematopoietic And Lymphoid Tissues Biology Blastoma CD19 Chronic Lymphocytic Leukemia Glioblastoma Health Sciences Hematopoietic Stem Cell Immune System Immunotherapies Lymphocytic Leukemia
        Hematologic Malignancies

        Hematologic malignancies are cancers of the blood, bone marrow, and lymphatic system. These cancers can affect the production and function of blood cells, leading to a variety of symptoms and complications. Common types of hematologic malignancies include leukemia, lymphoma, and multiple myeloma. Treatment for hematologic malignancies may include chemotherapy, radiation therapy, stem cell transplant, and targeted therapy.

        Browse All Tags